ClinicalTrials.gg
Active, not recruitingNCT07448155Updated Oct 29, 2026

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

A Phase 1 interventional study of INCA033989 and Bioavailability enhancer in Healthy Participants, sponsored by Incyte Corporation. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

Updated Oct 29, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • INCA033989
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend the study procedures, provide a signed ICF, and comply with all Protocol requirements.
  • Healthy, age 18 to 55 years, inclusive, at the time of signing the ICF, with no significant past or current medical history.
  • between 18.0 and 30.0 kg/m2, inclusive, at screening. Note: Up to 25% of the participants in each cohort may be enrolled with a BMI > 30 to ≤ 32.0 kg/m2.
  • No findings during screening and check-in (Day -1) for evaluations (eg, clinical, laboratory, vital signs, ). Tests with results that fail eligibility requirements may be repeated once during screening.
  • Ability to receive study treatment via IV or SC administration as per Protocol requirements.
  • Willingness to avoid pregnancy or fathering children.
  • Ability to understand and willingness to comply with study procedures and restrictions (including confinement to clinical site and restrictions of physical activity, use of recreational drugs, alcohol, and medications).

Exclusion criteria

Exclusion Criteria:

  • History of rheumatologic/ disorders, except for minor eczema and rosacea.
  • Participants with laboratory values outside the normal reference range at screening or check-in (see Appendix B for required analytes), including , WBC count, count, or , will be evaluated for clinical significance and eligibility by the investigator or qualified designee.
  • History of within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • Any major surgery within 4 weeks of screening.
  • Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for donation of plasma only).
  • Blood transfusion within 4 months of check-in (Day -1).
  • Chronic or current active infectious disease requiring systemic antibiotics or antifungal or antiviral therapy, including previously treated latent tuberculosis.
  • Positive test for , , or at screening. Participants with serologic findings consistent with prior HBV immunization or resolved HBV infection (eg, isolated anti HBs or anti-HBc positivity with negative HBsAg) may be included at the investigator's discretion.
  • History of chronic or recurrent edema or allergic conditions, including urticaria, allergic rhinoconjunctivitis, seasonal atopy, food allergy, or latex allergy.
  • History of alcoholism or significant alcohol use (medical or self-reported) within 3 months of screening, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females (1 unit = one-half pint of beer or a 25-mL shot of 40% spirit, 1.5-2 units = 125-mL glass of wine).
  • Consumption of alcohol within 72 hours prior to check-in (Day -1).
  • Receipt of any COVID-19 vaccines or any live (including attenuated) vaccines within 3 months prior to screening or anticipated need for such vaccines during the study.
  • Positive ethanol test (urine or breath) or positive urine drug screen for substances of abuse not attributed to permitted concomitant medications or dietary sources.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment with another medication or current enrollment/participation in another investigational drug or investigational product study.
  • History of anaphylaxis or severe reaction to any biologic therapy or injectable drug.
  • History of clinically significant drug allergies (eg, anaphylaxis, hepatotoxicity), as determined by the investigator.
  • Known hypersensitivity or severe allergic reaction to any of the INCA033989 components or (eg, polysorbate 80, citrate buffer), as documented in the IB.
  • Known hypersensitivity, allergy, or history of significant skin reactions to medical adhesives or adhesive-backed medical devices. This includes but is not limited to reactions to adhesive tapes, bandages, band-aids, and skin patches including acrylic based products.
  • History of tobacco use or use of nicotine-containing products within 2 weeks of screening.
  • Use of prescription medications (including hormonal ) within 14 days prior to study treatment administration, or use of nonprescription medication/products (including minerals, herbal, phytotherapeutic, or plant-derived preparations) within 7 days prior to study treatment administration. Occasional use of standard-dose acetaminophen, ibuprofen, and standard-dose vitamins is permitted. Megadose vitamins or supplements are not permissible.
  • Women who are pregnant or breastfeeding.
  • Any condition that, in the opinion of the investigator, may interfere with the participant's ability to fully comply with the study Protocol (including administration of the study treatment and attendance at required visits), pose a significant safety risk to the participant, or compromise the integrity of study data or its interpretation.
  • History of keloid formation or hypertrophic scarring, which may increase the risk of ISRs following SC dose administration, as determined by the investigator.
  • Abdominal tattoos or scarring at the injection site.
  • Previous treatment with INCA033989.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Cohort 1

    INCA033989 will be administered at protocol defined dose administered as a SC injection.

    Drug: INCA033989

  • Experimental
    Cohort 2

    INCA033989 will be administered at protocol defined dose administered as a SC injection.

    Drug: INCA033989

  • Experimental
    Cohort 3

    INCA033989 will be administered at protocol defined dose administered as an IV infusion.

    Drug: INCA033989

  • Experimental
    Cohort 4

    INCA033989 will be administered at protocol defined dose administered as a SC injection.

    Drug: INCA033989

  • Experimental
    Cohort 5

    INCA033989 in combination with a bioavailability enhancer will be administered at protocol defined dose administered as a SC injection.

    Drug: INCA033989 · Drug: Bioavailability enhancer

  • Experimental
    Cohort 6

    INCA033989 in combination with a bioavailability enhancer will be administered at protocol defined dose administered as a SC injection.

    Drug: INCA033989 · Drug: Bioavailability enhancer

  • Experimental
    Cohort 7

    INCA033989 in combination with a bioavailability enhancer will be administered at protocol defined dose administered as a SC injection.

    Drug: INCA033989 · Drug: Bioavailability enhancer

Interventions

  • INCA033989 will be administered at protocol defined dose.

  • DrugBioavailability enhancer

    A bioavailability enhancer will be administered with INCA033989 at protocol defined dose.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusion

    Defined as maximum observed plasma concentration of INCA033989.

    Time frame: Up to 12 weeks

  2. Pharmacokinetics Parameter: AUClast of INCA33989 following a single SC administration compared with a single IV infusion

    Defined as area under the concentration-time curve from time zero to time of the last quantifiable concentration (Clast) of INCA033989.

    Time frame: Up to 12 weeks

  3. Pharmacokinetics Parameter: AUC0∞ of INCA33989 following a single SC administration compared with a single IV infusion

    Defined as area under the single-dose concentration-time curve extrapolated to time of infinity of INCA033989.

    Time frame: Up to 12 weeks

  4. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or the worsening of a pre-existing event, occurring after study drug administration.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Pharmacokinetics Parameter: tmax of INCA33989 following a single SC administration

    Defined as time to maximum concentration of INCA33989.

    Time frame: Up to 12 weeks

  2. Pharmacokinetics Parameter: t1/2 of INCA33989 following a single SC administration

    Defined as the apparent terminal phase disposition half-life of INCA33989.

    Time frame: Up to 12 weeks

  3. Pharmacokinetics Parameter: CL/F of INCA33989 following a single SC administration

    Defined as the apparent dose clearance of INCA33989.

    Time frame: Up to 12 weeks

  4. Pharmacokinetics Parameter: Vz/F of INCA33989 following a single SC administration

    Defined as the apparent volume of distribution of INCA033989.

    Time frame: Up to 12 weeks

  5. Pharmacokinetics Parameter: tmax of INCA33989 following a single IV infusion

    Defined as time to maximum concentration of INCA33989.

    Time frame: Up to 12 weeks

  6. Pharmacokinetics Parameter: t1/2 of INCA33989 following a single IV infusion

    Defined as the apparent terminal phase disposition half-life of INCA33989.

    Time frame: Up to 12 weeks

  7. Pharmacokinetics Parameter: CL of INCA33989 following a single IV infusion

    Defined as the total systemic clearance of INCA033989.

    Time frame: Up to 12 weeks

  8. Pharmacokinetics Parameter: Vss of INCA33989 following a single IV infusion

    Defined as the volume of distribution at steady state of INCA033989.

    Time frame: Up to 12 weeks

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 4, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Nov 14, 2026was Oct 2026
CompletionEst.
Nov 14, 2026was Oct 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Primary completion
Oct 19, 2026→Nov 14, 2026
Oct 29, 2026
Study completion
Oct 19, 2026→Nov 14, 2026
Oct 29, 2026
Enrollment
126 (estimated)→108 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 19, 2026→Nov 14, 2026
    Study completion Oct 19, 2026→Nov 14, 2026
    Enrollment 126 (estimated)→108 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07448155
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 19, 2026
Primary completion
Nov 14, 2026 (estimated)
Completion
Nov 14, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-mutant Calreticulin Monoclonal Antibody INCA033989

Start the discussion